Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Motoya

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Digestion|January 5, 2017
Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective StudyMasanao Nasuno, Maki Miyakawa, Hiroki Tanaka, et al.
Journal of Gastroenterology|April 9, 2009
Sargramostim in patients with Crohn's disease: results of a phase 1-2 studyMasakazu Takazoe, Toshiyuki Matsui, Satoshi Motoya, et al.
Journal of Crohn'S & Colitis|July 7, 2012
Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II studyYasuo Suzuki, Satoshi Motoya, Masakazu Takazoe, et al.
Diseases of the Colon and Rectum|February 16, 2008
Association of SLC22A4/5 polymorphisms with steroid responsiveness of inflammatory bowel disease in JapanSeiya Nakahara, Yoshiaki Arimura, Katsuhiko Saito, et al.
Gastroenterology|September 2, 2015
Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative ColitisNaoki Yoshimura, Mamoru Watanabe, Satoshi Motoya, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|October 12, 2016
A case of Takayasu's arteritis detected in a patient with Crohn's disease following infliximab treatmentMaki Miyakawa, Hiroki Tanaka, Masaki Yamashita, et al.
Crohn'S & Colitis 360|February 13, 2023
Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn's Disease: A Retrospective Cohort StudyTakahiro Ito, Atsuo Maemoto, Takehiko Katsurada, et al.
Inflammatory Intestinal Diseases|June 21, 2018
Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 StudyTadashi Yokoyama, Akihiko Ohta, Satoshi Motoya, et al.
Journal of Gastroenterology|July 12, 2015
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysisTaku Kobayashi, Yasuo Suzuki, Satoshi Motoya, et al.
Intestinal Research|November 29, 2020
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Digestion|January 5, 2017
Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective StudyMasanao Nasuno, Maki Miyakawa, Hiroki Tanaka, et al.
Journal of Gastroenterology|April 9, 2009
Sargramostim in patients with Crohn's disease: results of a phase 1-2 studyMasakazu Takazoe, Toshiyuki Matsui, Satoshi Motoya, et al.
Journal of Crohn'S & Colitis|July 7, 2012
Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II studyYasuo Suzuki, Satoshi Motoya, Masakazu Takazoe, et al.
Diseases of the Colon and Rectum|February 16, 2008
Association of SLC22A4/5 polymorphisms with steroid responsiveness of inflammatory bowel disease in JapanSeiya Nakahara, Yoshiaki Arimura, Katsuhiko Saito, et al.
Gastroenterology|September 2, 2015
Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative ColitisNaoki Yoshimura, Mamoru Watanabe, Satoshi Motoya, et al.
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|October 12, 2016
A case of Takayasu's arteritis detected in a patient with Crohn's disease following infliximab treatmentMaki Miyakawa, Hiroki Tanaka, Masaki Yamashita, et al.
Crohn'S & Colitis 360|February 13, 2023
Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn's Disease: A Retrospective Cohort StudyTakahiro Ito, Atsuo Maemoto, Takehiko Katsurada, et al.
Inflammatory Intestinal Diseases|June 21, 2018
Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 StudyTadashi Yokoyama, Akihiko Ohta, Satoshi Motoya, et al.
Journal of Gastroenterology|July 12, 2015
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysisTaku Kobayashi, Yasuo Suzuki, Satoshi Motoya, et al.
Intestinal Research|November 29, 2020
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.
Pageof 9